30482-25-8

Basic information

• Product Name: 8-AMinoMethyl-1,4-dioxaspiro[4.5]decane
• Synonyms: 8-AMinoMethyl-1,4-dioxaspiro[4.5]decane;1,4-Dioxaspiro[4.5]decane-8-MethanaMine;1,4-Dioxaspiro[4.5]decan-8-ylMethanaMine;(1,4-dioxa-spiro[4.5]dec-8-yl)-Methyl-aMine
• CAS NO: 30482-25-8
• Molecular Formula: C₉H₁₇NO₂
• Molecular Weight: 171.23678
• Mol File: 30482-25-8.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 270.059 °C at 760 mmHg
• Flash Point: 126.861 °C
• Appearance: /
• Density: 1.088 g/cm³
• Vapor Pressure: 0.007mmHg at 25°C
• Refractive Index: 1.505
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 10.20±0.29(Predicted)
• CAS DataBase Reference: 8-AMinoMethyl-1,4-dioxaspiro[4.5]decane(CAS DataBase Reference)
• NIST Chemistry Reference: 8-AMinoMethyl-1,4-dioxaspiro[4.5]decane(30482-25-8)
• EPA Substance Registry System: 8-AMinoMethyl-1,4-dioxaspiro[4.5]decane(30482-25-8)

Safety Data

• Hazardous Substances Data: 30482-25-8(Hazardous Substances Data)

Usage

Description

8-Aminomethyl-1,4-dioxaspiro[4.5]decane is an organic compound characterized by its unique molecular structure, which features a spirocycle with a 1,4-dioxaspiro framework and an aminomethyl group at the 8th position. 8-AMinoMethyl-1,4-dioxaspiro[4.5]decane is known for its potential applications in various fields due to its chemical properties and reactivity.

Uses

Used in Pharmaceutical Industry:
8-Aminomethyl-1,4-dioxaspiro[4.5]decane is used as a key intermediate in the synthesis of brain-penetrating cathepsin S inhibitors. Cathepsin S is a lysosomal cysteine protease that has been implicated in various neurological disorders and diseases, such as Alzheimer's, Parkinson's, and multiple sclerosis. By inhibiting the activity of cathepsin S, these inhibitors can potentially help in the treatment and management of these conditions.

InChI:InChI=1/C9H17NO2/c10-7-8-1-3-9(4-2-8)11-5-6-12-9/h8H,1-7,10H2

Upstream product

• 30482-24-7 1,4-dioxaspiro<4,5>decane-8-carboxamide 
• 69947-09-7 1,4-dioxaspiro<4.5>decane-8-carbonitrile 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 23521-81-5 (1,4-dioxaspiro[4.5]dec-8-yl)methanol 
• 1489-97-0 ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 147767-55-3 (1,4-dioxaspiro[4.5]dec-8-yl)methyl methanesulfonic acid 
• 26845-47-6 methyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 

Downstream Products

• 42949-24-6 1-azaadamantane-4-one 
• 423116-18-1 2-[(4-oxocyclohexyl)methyl]isoindoline-1,3-dione 
• 69947-09-7 1,4-dioxaspiro<4.5>decane-8-carbonitrile 
• 444199-08-0 (+/-)-4,5,6,7-tetrahydro-2H-izoindol-5-ylmethanamine 
• 423116-19-2 2-{[4-(hydroxyimino)cyclohexyl]methyl}isoindoline-1,3-dione 
• 423116-20-5 2-{[4-(prop-2-enyloxyimino)cyclohexyl]methyl}isoindoline-1,3-dione 
• 401947-08-8 (6S,8aS)-4-Oxo-2-phenylmethanesulfonyl-octahydro-pyrrolo[1,2-a]pyrazine-6-carboxylic acid (4-oxo-cyclohexylmethyl)-amide 
• 867023-69-6 4,5,6,7-tetrahydro-2H-indazol-5-ylmethanamine 
• 869895-16-9 benzyl 1,4-dioxaspiro[4.5]dec-8-ylmethylcarbamate 

Relevant articles and documents

A short synthesis of 1-azaadamantan-4-one and the 4r and 4s isomers of 4-amino-1-azaadamantane

Reductive homologation of 1,4-cyclohexanedione monoethylene acetal (1) with tosylmethylisocyanide and subsequent reduction with lithium aluminum hydride gave 1,4-dioxaspiro[4.5]decan-8-yl-methylamine (3) which was converted to 1-azatricyclo[3.3.1.13,7] decan-4-one (4) via a known double-Mannich condensation. Reductive amination of this ketone gave the corresponding 1-azatricyclo[3.3.1.13,7]decan-4 (s and r)-amines (9 and 10) which were separated on a multigram scale as their corresponding tosylamides 7 and 8, followed by deprotection.

PYRIDINYL PYRAZOLES AS MODULATORS OF RORyT

The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORgT

The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.